Turn Biotechnologies

Turn Biotechnologies is pursuing cellular reprogramming through arguably the safest available modality — transient mRNA rather than integrating viral gene therapy — and that engineering choice is its central advantage. Its ERA (Epigenetic Reprogramming of Aging) platform delivers combinations of transcription factors via lipid nanoparticles that express only briefly, restoring youthful gene expression without altering DNA or driving cells to full pluripotency, giving Turn a controllable, dose-tunable, redosable approach where AAV-based rivals are locked into a one-shot, irreversible payload. The data has centered on skin, where ERA reportedly reversed more than a decade of aging in fibroblasts and keratinocytes ex vivo, and lead candidate TRN-001 is targeting clinical entry around 2026 following positive FDA meeting feedback — a tangible near-term milestone in a field long on promise and short on clinic dates. The commercial architecture is capital-smart: a global licensing agreement with HanAll Biopharma (and Daewoong) worth up to a potential $300M covers eye and ear disease programs and supplies non-dilutive funding plus pharma validation on a company that has raised only ~$30M directly, while the March 2025 acquisition of Harvard-developed ARMMs delivery technology broadens its toolkit beyond LNPs. Skin offers visible, cheap endpoints to prove the platform before the harder systemic indications. Founded on Stanford reprogramming science with Vittorio Sebastiano among its co-founders, Turn pairs a credible team with the field's most deliverable rejuvenation modality.